Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Tomoaki Kamiyoshihara"'
Autor:
Hidenobu Kondo, Kenji Fujisawa, Yukikazu Hayashi, Takuhiro Yamaguchi, Toshiaki Nojima, Hideki Suganami, Tomoaki Kamiyoshihara, Hisataka Fujiwara, Ryohei Tanigawa
Publikováno v:
Therapeutic Innovation & Regulatory Science
Background Risk-based monitoring (RBM) is a slow uptake in some trial sponsors. There are three main reasons for this. First, there is the fear of making large investments into advanced RBM technology solutions. Second, it is considered that RBM is m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83789ce8a9a3288ca158d342281f685f
http://europepmc.org/articles/PMC8238712
http://europepmc.org/articles/PMC8238712
Autor:
Kenji Uéda, Tomoaki Kamiyoshihara, Hiroshi Kihara, Mitsuru Tashiro, Sakurako Shimotakahara, Kouki Kasai, Masaki Kojima
Publikováno v:
Biochemical and biophysical research communications. 369(3)
alpha-Synuclein is the major component of the filamentous Lewy bodies and Lewy-related neurites, neuropathological hallmarks of Parkinson's disease. Although numerous studies on alpha-synuclein fibrillation have been reported, the molecular mechanism
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34c5866eb69517e736666ff0b0457d6e
https://pubmed.ncbi.nlm.nih.gov/18329380
https://pubmed.ncbi.nlm.nih.gov/18329380
Publikováno v:
Biochemical and biophysical research communications. 355(2)
One of the most well known characteristics for Parkinson's disease (PD) is a polymerization of wild-type or mutant alpha-synuclein into aggregates and fibrils, commonly observed as Lewy bodies and Lewy neuritis in PD patients. Although numerous studi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b46dff5099719e4ae872b251e90995c
https://pubmed.ncbi.nlm.nih.gov/17300751
https://pubmed.ncbi.nlm.nih.gov/17300751